Komori
Medikit (7749) · InitiativeAdvanced

Strengthening production capabilities through a division of roles between domestic and Vietnam sites

First written in FY2016. 5 of 8 entries say "Advanced", first in FY2018. Latest entry: FY2026.

8entries
11years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016AdvancedFY2018 – FY2021RestatedFY20222016: 120162017: 020172018: 120182019: 020192020: 020202021: 120212022: 120222023: 020232024: 020242025: 120252026: 32026
Same theme, other companies
Establishing an optimal production structure across domestic and overseas plantsA theme 116 companies write about · 0 as a headwind · 121 as a tailwind

71 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 116 companies compared. The sentences above are computed from all 116.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「During the consolidated fiscal year, we made capital investments totaling ¥2,216.022 million in property, plant and equipment and intangible assets. The main investment was the acquisition of production equipment.」

    To strengthen production capabilities, the company made ¥2,216.022 million of capital investments during the fiscal year and acquired production equipment.
  2. FY2025AdvancedAnnual report

    「During the consolidated fiscal year, we made capital investments totaling ¥4,441.931 million in property, plant and equipment and intangible assets. The main investments were the expansion of the Hyuga No. 2 Plant, the construction of the Hyuga No. 3 Plant, and the acquisition of production equipment.」

    The division of roles between domestic bases and stronger production capabilities have been made concrete through ¥4,441.931 million of capital investment, including the expansion of the Hyuga No. 2 Plant, construction of the Hyuga No. 3 Plant, and acquisition of production equipment.
  3. FY2022RestatedAnnual report

    「We will strengthen quality and cost management to maximize the Group's technologies and production capacity, work to enhance competitiveness, and promote a stronger, efficient and flexible production management system.」

    The company continues to strengthen competitiveness through quality and cost management and to reinforce an efficient and flexible production management system.
  4. FY2021AdvancedAnnual report

    「We will strengthen quality and cost management to maximize the Group's technologies and production capacity, work to enhance competitiveness, and promote a stronger, efficient and flexible production management system.」

    The company has translated stronger production capabilities into specific annual objectives: strengthening quality and cost management and reinforcing an efficient and flexible production management system.
  5. FY2018AdvancedAnnual report

    「We will clarify the division of responsibilities and roles between our domestic and Vietnam production bases, produce high-quality products efficiently and flexibly, and promote stronger production capabilities. As increased sales volumes require more efficient production, we have proceeded with the consolidation and discontinuation of products as appropriate.」

    The company states that, in addition to dividing roles between its bases, it consolidated and discontinued products during the period, demonstrating concrete measures to improve production efficiency.
  6. FY2016First statedAnnual report

    「We will clarify the division of responsibilities and roles between our domestic and Vietnam production bases, produce high-quality products efficiently and flexibly, and promote stronger production capabilities.」

    The company plans to link the division of responsibilities and clarification of roles between its bases to improvements in production quality, efficiency and flexibility.
Moved together

"Launch and Improvement of Products with Safety Mechanisms and New Catheter Products" moved the same way as this thread, in the same document, in 4 of its 8 moves.

444333★123456
  1. ★This thread
  2. 1Launch and Improvement of Products with Safety Mechanisms and New Catheter Products4×
  3. 2Obtaining Overseas Certifications and Expanding into the US and European Markets4×
  4. 3Enhancement of Component Production Capacity at the Hyuga Plant and Hyuga No. 2 Plant4×
  5. 4Retained Earnings for Stable Dividends, Development and Investment3×
  6. 5Establishing a Framework for Global Business Expansion3×
  7. 6R&D Focus on Safety Mechanisms, Existing Product Improvements and Catheter Applications3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Medikit's next results are scheduled for 2026-11-12. Read the earnings preview It last moved in the General Meeting of Shareholders of 2026-06-03: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening production capabilities through a division of roles between domestic and Vietnam sites | MEDIKIT CO.,LTD. (7749) | Komori